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Abstract
 .CTP:phosphocholine cytidylyltransferase CT , the rate controlling enzyme in phosphatidylcholine biosynthesis, is
activated by reversible membrane binding. To investigate the membrane binding mechanism of CT, we have used the
 .  w125 x . w125 x .photoreactive hydrophobic probe 3- trifluoromethyl -3- m- I iodophenyl diazirine I TID . Association of CT with
 .phosphatidylcholineroleic acid 1:1 vesicles was first demonstrated by gel filtration analysis. Upon irradiation, CT was
w125 xcovalently labeled by I TID presented in phosphatidylcholineroleic acid vesicles. This demonstrates an intercalation of
part of the protein into the hydrophobic core of the membrane. To identify the membrane-embedded domain, the
w125 xchymotrypsin digestion products of I TID labeled CT were analysed. Chymotrypsin digestion produced a set of
  . .previously defined N-terminal fragments Craig, L., Johnson, J.E. and Cornell, R.B. 1994 J. Biol. Chem. 269, 3311 , as
well as several small C-terminal fragments which react with an anti-peptide antibody raised against the proposed
w125 xamphipathic a-helix. All fragments containing the amphipathic helical region of the enzyme had I TID label associated,
while the chymotryptic fragment which lacked this region was not highly labeled. Similar fragment labeling patterns were
w125 xproduced when I TID was presented in phosphatidylcholineroleic acid or phosphatidylcholinerdiacylglycerol vesicles,
suggesting that the same domain of CT mediates binding to membranes containing either of the two lipid activators. A
w125 x62-residue synthetic peptide corresponding in sequence to the amphipathic helical region of CT was labeled with I TID,
demonstrating its ability to intercalate independently of the rest of the protein. These results indicate a membrane-binding
mechanism for cytidylyltransferase involving the intercalation of the amphipathic a-helix region into the hydrophobic acyl
chain core of the activating membrane.
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1. Introduction
 .CTP:phosphocholine cytidylyltransferase CT ,
which catalyses a key regulatory step in the biosyn-
 .thesis of phosphatidylcholine PC in mammalian
systems, is an amphitropic enzyme that is regulated
by reversible binding to membranes. PC is the major
phospholipid component of animal cell membranes,
and thus its breakdown and resynthesis must be
w xcoordinated 1–3 . Knowledge of how CT is regu-
lated is central to the understanding of how cellular
levels of PC are controlled in response to agonist
induced PC turnover.
The exact mechanism for membrane binding and
subsequent activation of CT is not known, although
the key stimulus appears to be the lipid composition
of the membrane. Membranes composed solely of PC
poorly activate the enzyme while those containing
w xanionic phospholipids and fatty acids 4–6 or neutral
lipids with small polar head groups such as diacyl-
w xglycerol 7–10 are potent activators. The presence of
cationic lipids such as sphingosine inhibits enzyme
w xactivation 11 . Both electrostatic and hydrophobic
interactions have been implicated in the binding pro-
w xcess 6,10,12 . Cell culture studies have demonstrated
a dephosphorylation event concurrent with or subse-
w xquent to membrane binding 13–16 . Dephosphoryla-
tion appears to be secondary to changes in lipid
composition as a trigger for membrane binding
w x14,17 .
On the basis of structural predictions and homolo-
w xgies of the primary sequence 18 , we have proposed
a tripartite model for the domain structure of CT Fig.
.1 .
 .i The N-terminal two-thirds forms a discrete,
w xproteinase insensitive domain 19 . This domain is
proposed to house the catalytic site based on its
Fig. 1. Model for the domain structure of CT.
w xsequence homology with yeast CT 20 and a related
B. subtilis glycerol phosphate cytidylyltransferase
w x21,22 , as well as a study of a mutant in this region
w x  .defective in CTP binding 23 . ii The C-terminal 55
residues are rich in serine-proline motifs that are
potential substrates for cyclin dependent kinases, and
contain a potential site for casein kinase II. This
domain is highly phosphorylated in vivo and in vitro
w x24–26 , although the function of phosphorylation is
 .not yet established. iii The ;60 residue region
linking the catalytic and phosphorylation domain is
predicted to be an amphipathic a-helix, which we
w xhave proposed to mediate membrane binding 18 .
This type of structure mediates the membrane interac-
tions of several other proteins, including apolipo-
w x w xproteins 27,28 , prostaglandin H synthase-1 29 ,2
w x w xFactor VIII 30 , and various lytic peptides 31 .
Evidence to support involvement of the putative
amphipathic a-helix region of CT in membrane bind-
 .ing has emerged recently. i Chymotrypsin proteoly-
sis of CT produced discrete fragments that were
mapped to the N-terminus and were missing various
amounts of the C-terminal region of the protein.
Those fragments which lacked all or part of the
putative amphipathic helical region were unable to
w x  .bind to lipid vesicles 19 . ii Spectroscopic studies
of a 33-residue synthetic peptide corresponding to the
C-terminal half of the amphipathic helix domain
demonstrated that the peptide was induced into a
helical conformation by anionic lipids and interca-
lated into the acyl chain region of anionic lipid
w x  .vesicles with a selectivity for anionic lipids 32 . iii
CT deletion mutants lacking this domain that were
expressed in COS or CHO cells, had a decreased
w x  .association with the membrane fraction 25,33 . iv
Antibodies directed against a 10 amino acid segment
w xof this region inhibited membrane binding 34 . While
there is evidence for a requirement for the amphi-
pathic helical domain in CT-membrane interactions,
the results of previous studies do not rule out an
indirect effect of this helical region on membrane
binding. Although synthetic peptides corresponding
to the amphipathic helix domain bind to lipid vesi-
cles, it had not been shown directly using the whole
enzyme that this region contacts and intercalates into
the membrane. Furthermore, the synthetic peptide
bound only to vesicles containing anionic lipids, but
not to vesicles containing the lipid activator, diacyl-
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w xglycerol 32 . This raised the possibility that the
amphipathic helix domain was not responsible for
binding to vesicles containing DAG.
In this report, we have applied the technique of
w xhydrophobic photolabeling 35 to directly determine
the regions of the CT protein that intercalate into the
hydrophobic core of the membrane. The hydrophobic
 . p r o b e 3 - t r i f l u o r o m e t h y l - 3 - m -
w125 x . w125 x .I iodophenyl diazirine I TID partitions
specifically into the hydrophobic membrane core
w x36,37 . Photoactivation of the diazirine functional
group produces a highly reactive carbene species
which has the potential to react non-selectively with
any molecule in the vicinity. Thus, any regions of the
protein which are embedded in the hydrophobic core
of the membrane should become labeled by the probe.
This technique has been used to identify membrane
interacting regions of integral membrane proteins,
w xsuch as bacteriorhodopsin 38 , a light-harvesting pro-
w xtein B870 39 , the nicotinic acetylcholine receptor
w x40 ; as well as amphitropic intercalating proteins
w x w xsuch as synapsin I 41 , Sec A 42 and a soluble
w xfragment of hemagglutinin 43,44 . Using a combina-
tion of photolabeling, proteolysis and amino acid
sequencing, we have determined that a region of
membrane-bound CT does indeed penetrate into the
hydrophobic core, and that this region corresponds to
the amphipathic helical region of the protein.
2. Experimental procedures
2.1. Materials
A 62 residue peptide corresponding to the putative
amphipathic helix region of rat liver CT residues
.238 to 299 was synthesized and HPLC purified by
 .Dr. Ian Clark-Lewis University of British Columbia
w xas described 45 . The peptide was )97% pure as
assessed by analytical reverse-phase HPLC. Its amino
acid composition was consistent with its expected
w125 x w 3 x wsequence. I TID, methyl- H DPPC and 1-
14 x wC oleic acid were from Amersham, and phenyl-
3 xH Triton X-100 was from DupontrNEN. Egg PC
was from Avanti. sn-1,2-diacylglycerol was gener-
ated by digestion of egg PC using phospholipase C as
w x described 46 . Oleic acid, a-Chymotrypsin Type II:
.from bovine pancreas , Ovalbumin, Sephacryl-S400-
HR, and the goat-anti-rabbit horseradish peroxidase
antibody were from Sigma. PVDF was from Biorad.
 .BSA fraction V, fatty acid free was from Cal-
biochem. Rat liver CT recombinant baculovirus, Tri-
 .chopusia ni T. ni cells and antiserum raised against
a C-terminal peptide of CT were kindly provided by
 .Dr. Claudia Kent U. Michigan . Apolipoprotein A-I
was kindly provided by Dr. R.J. Cushley Simon
.Fraser U. Rabbit antiserum against the N-terminus of
w xCT was prepared as described 25 . Antiserum against
the amphipathic helix was generated as follows: A
synthetic peptide corresponding to residues 256–288
with an additional N-terminal cysteine was coupled
 .to keyhole limpet hemocyanin KLH using suc-
 .cimidyl 4- N-maleimidomethyl cyclohexane-1-
 w x.carboxylate Pierce; 47 . Rabbit antiserum was gen-
erated by monthly subcutaneous injections with 50
mg KLH conjugated peptide in Freunds incomplete
adjuvent. The blood was collected from the ear vein
10 days post-injection. Electrophoresis reagents were
Molecular Biology Grade purchased from BRL or
Sigma.
2.2. Methods
Purification of CT: Recombinant rat liver CT was
expressed in T. ni insect cells using a baculovirus
w xexpression system and purified as described 48 with
w xsome revisions 25 . The pure enzyme was stored in a
stabilizing buffer containing 0.05% Triton X-100.
[125 ]2.2.1. I TID photolabeling
w125 x  .I TID 0.2 to 2 mol% of total lipid was prein-
cubated 10 min at room temperature with sonicated
 .PCroleic acid 1:1 vesicles or PCrdiacylglycerol
 .  .4r1 vesicles ref. 10 in 10 mM Tris, pH 7.4, 1
 .mM EDTA, 1 mM DTT. CT ;20 mg was added
so that the final Triton X-100 concentration was
-20 mol% of the total lipid, and the CT:lipid molar
ratio was 1:300. For photolabeling of the peptide,
w125 xI TID and PCroleic acid were preincubated in 10
mM Tris, pH 7.4, 1 mM EDTA, and the peptide was
 .added 1:200, peptiderlipid molar ratio . After a 10
min incubation at room temperature, the protein-lipid
mixture was transferred to a 1 ml quartz cuvette. All
samples were irradiated for 10 min at room tempera-
ture using a 100 W Hg lamp with a filter to exclude
light -300 nm.
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2.2.2. Partial digestion of CT with chymotrypsin
After photolysis, the CT-lipid mixture was par-
tially digested with chymotrypsin as previously de-
w xscribed 19 . Samples were incubated with proteinase
at the indicated chymotrypsin:CT mass ratio for 10–
15 min at 378C, at which time the reaction was
terminated by addition of PMSF to a final concentra-
tion of 2 mM.
2.2.3. Gel electrophoresis
Samples containing whole or digested CT were
prepared for electrophoresis by extensive dialysis
 .MWCO of 3500 against 10 mM Tris, pH 7.5, 0.5
mM EDTA, 0.005% SDS, 2 mM DTT, 0.05% BSA
 .fatty acid free . For chymotrypsin-digested samples,
0.5 mM PMSF was included in the dialysis buffer.
Samples were concentrated in a Savant Speed-Vac
evaporator prior to addition of sample buffer. CT and
large fragments were separated on a 12% polyacryl-
w xamide gel by the method of Laemmli 49 . Small CT
fragments were separated on a 16.5%Tr3%C Tricine
gel system 2 by the method of Schagger and von
w xJagow 50 . In both cases, the portion of the gel
containing the bromphenol blue dye-front was ex-
cised, as it contained labeled lipid present in the
sample.
Samples containing peptide were delipidated prior
to electrophoresis by precipitation with cold acetone
at y808C for 3–8 h, followed by a wash with cold
diethyl ether. The resulting precipitate was resus-
pended in sample buffer and electrophoresed
overnight at 48C on a 16.5%Tr6% C polyacrylamide
gel with a 1 cm 10%Tr3%C spacer between the
w xstacking and separating gels 50 .
2.2.4. Protein and radioacti˝ity quantitation
For autoradiography, 125I-containing gels were
Coomassie stained, dried, and exposed to preflashed
 .Reflections film Dupont with an intensifying screen
 .Dupont at y808C for the indicated time. Protein
mass associated with the bands was estimated using a
Microtek Scanmaker densitometer with NIH imaging
software. 125I-labeling was quantified in excised bands
by gamma-counting.
2  .T refers to the total percent wrv concentration of both
acrylamide monomers C refers to the percent of total acrylamide
that is the crosslinker bisacrylamide.
2.2.5. Immunoblotting
After separation by electrophoresis as described
above, proteins were transferred to PVDF membrane
using a Pharmacia LKB Novablot system at 2
2 w xmArcm for 1 to 1.5 h as described 19 . Immunore-
w xactions were as described 25 .
2.2.6. Sequence analysis
For N-terminal sequencing, chymotryptic frag-
ments of CT were electrophoresed in the Tricine gel
system, transferred to PVDF membrane and stained
with Amido Black. The detected bands were cut out
and subjected to N-terminal sequencing in an Applied
Biosystems model 477A protein sequencer equipped
with an on-line model 120A PTH analyzer following
standard operating procedures.
2.2.7. Gel filtration analysis of CT binding to PCr
oleic acid ˝esicles
The association of CT with PCroleic acid vesicles
w xwas analysed by gel filtration 6 . CT was incubated
with PCroleic acid vesicles 1:350 protein to lipid
.molar ratio, 4 mM total lipid or with Triton X-100
 .micelles 10 mM for 10 min at room temperature.
w3 x w14 x w3 xH DPPC, or C oleic acid and H Triton X-100
w3 xwere included in trace amounts. H Triton X-100
was vortexed with preformed vesicles, while
w3 x w14 xH DPPC or C oleic acid was sonicated with the
unlabeled lipids during vesicle preparation. The sam-
ple was loaded on a Sephacryl-S400 column 44.5
.cm=1 cm that had been pre-equilibrated with col-
umn buffer 10 mM Tris, pH 7.5, 1 mM EDTA, 0.5
.mM Triton X-100, 2 mM DTT and run at 0.3
 .mlrmin. Fractions ;0.9 ml were collected and
 . 3 14samples analysed 1 for Hr C-labeled lipid by
 .scintillation counting; and 2 for CT by gel elec-
trophoresis and subsequent densitometry of the
Coomassie-stained gels. The void volume and total
volume of the column were identified using Blue-De-
w3 xxtran and H glycerol, respectively.
3. Results
3.1. Gel filtration analysis of CT binding to PCroleic
acid ˝esicles
w125 xOur objective was to photoreact CT with I TID
under conditions where all of the CT was in the
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membrane-bound form. The purified CT was ob-
tained bound to Triton X-100 micelles, to which we
added egg PCroleic acid vesicles containing traces
w125 xof I TID. The resulting PCroleic acidrTriton X-
100 ratio was 2:2:1. This mixture forms vesicles that
w xfully activate CT 6 . Sephacryl S400 gel filtration
chromatography was used to analyse the degree of
binding of CT to the vesicles under photolysis condi-
 .tions Fig. 2 . In the presence of Triton X-100 mi-
celles alone, CT eluted slightly ahead of the peak of
 .Triton X-100 radioactivity Fig. 2A . Since Triton
Fig. 2. Gel filtration analysis of the binding of CT to PCroleic
acid vesicles. The samples applied to the Sephacryl-S400 column
were prepared and chromatographed, and fractions were analysed
w14 xfor radioactivity and CT as described in Section 2.2. C oleic
w3 xacid was incorporated into the vesicles and H Triton X-100 was
 .added to the samples in trace amounts. A Chromatography of
 .CT plus 10 mM Triton X-100. B Chromatography of CT plus 4
 .mM PCroleic acid 1:1 vesicles. The lipid to protein molar ratio
in this sample was 350:1; the Triton X-100 content was 20 mol%
 . w3 x  .of the total amphiphile. CT protein v , H Triton X-100 I ,
w14 x  .C oleic acid ^ .
 .X-100 was in large excess 10 mM , the bulk of the
detergent was in the form of a protein-free micelle
 .90 000 daltons . CT associates with Triton X-100 as
w xa 84 kDa dimer 51 , thus the few micelles containing
protein would be significantly bigger and elute ear-
lier. The size of Triton X-100 micelles containing a
CT molecule was previously estimated at ;2P105
w xdaltons, by Sephacryl S-400 chromatography 6 .
In the presence of PCroleic acidrTriton X-100
 .2:2:1 , the conditions used for the photolabeling
reaction, CT eluted earlier than in the presence of
 . w14 xTriton X-100 alone Fig. 2A and B . C Oleic acid
was incorporated into the vesicles as a tracer. In some
w3 xexperiments, H DPPC was incorporated into the
w14 xvesicles instead of C oleic acid, and eluted at the
same volume as did the oleic acid, demonstrating that
w14 xthe two lipids remain complexed. C Oleic acid or
w3 xH DPPC, along with a small amount of the Triton
X-100, eluted early in the column presumably as
 .large vesicles in the absence data not shown or
 .presence of CT Fig. 2B . In the presence of PCroleic
acid, CT eluted from the column as a single peak
corresponding exactly to the peak of radiolabeled
w14 xC oleic acid, and much earlier than the peak of
3H-labeled Triton X-100 present in the sample. No
CT protein eluted in fractions between 26 to 29 ml
where CT was found when mixed with Triton X-100
 .only Fig. 2A . We conclude that 100% of the CT in
the sample was bound to PCroleic acid vesicles
under these conditions, which were the same as those
used in the photolabeling experiment.
[125 ]3.2. I TID labeling of CT in the presence of
PCroleic acid ˝esicles
w125 xPurified CT was photoreacted with I TID in-
 .corporated into PCroleic acid vesicles 1:1 . Irradia-
tion of the enzyme under the conditions described did
 .not affect the CT activity data not shown . Elec-
trophoresis was utilized to separate the protein from
lipid, which migrated at the dye front and contained
)99% of the label. As seen in Fig. 3, CT was
w125 xsignificantly labeled by I TID. CT contained 0.03
to 0.05% of the total label added. When 0.2 mol%
w125 xI TID was used, approximately 1 in 5000 CT
w125 xmolecules became labeled, while at 1 mol% I TID,
an estimate of 1 in 650 CT monomers had label
associated. The lack of stoichiometric labeling of CT
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does not imply that 100% of the molecules present
are not bound and intercalated in the membrane. TID
photolabeling is a trace labeling technique. When
TID is activated by irradiation, the carbene formed
reacts quickly and with low specificity with any
molecule in the vicinity. It can react with methylene
groups of the acyl chains of lipid and, as the lipid is
in large excess, the bulk of the label becomes lipid
associated. To demonstrate the selectivity for mem-
brane interacting proteins, a soluble protein, ovalbu-
min, was subjected to photolabeling under the same
conditions as CT. Unlike CT, ovalbumin did not
co-elute with lipid vesicles when analyzed by
Sephacryl S-400 chromatography. Ovalbumin was
not significantly labeled by the probe Fig. 3B, lane
.2 . Apolipoprotein A-I, which associates with PC
w x32 , is also thought to interact with membranes via
w xan amphipathic helix 27 . When reacted with
w125 xI TID in the presence of PC vesicles under the
same conditions as CT, this protein was labeled to
approximately the same extent as CT Fig. 3B, lane
.3 .
In a similar set of experiments, vesicle-bound CT
was photolabeled with a distinct hydrophobic probe,
w w  . x x11- 4- 3- trifluorom ethyl d iaziriny l phenyl -
w 3 x w3 x .2 H undecanoic acid H TUA . This photoreactive
w125 xFig. 3. I TID labeling of CT and control proteins. Proteins
w125 x  .were labeled with I TID 0.2 mol%, 3 mCi in vesicles as
described in Section 2.2. Samples were electrophoresed on a 12%
 .  .acrylamide gel. A Gel stained with Coomassie blue. B Au-
 .toradiograph of dried gel, exposed for 20 h. Lane 1: CT 20 mg
 .labeled in the presence of 0.75 mM PCroleic acid 1:1 . Lane 2:
 .ovalbumin 12 mg labeled in the presence of 0.75 mM PCroleic
 .  .acid 1:1 . Lane 3: apolipoprotein A-I 11 mg labeled in the
presence of 0.5 mM PC. The positions of molecular weight
standards are shown.
Fig. 4. Proposed CT fragments generated by chymotryptic diges-
tion. The large 39, 35 and 26 kDa fragments were mapped by
 .Craig et al. 1994 . The N-terminal residues of the low molecular
weight fragments of M s19, 17, 15 and 11 kDa were deter-ap
mined by N-terminal sequencing. The 19 kDa fragment contains
the C-terminal residues determined by antibody mapping, Fig.
.6 , and has a calculated molecular weight of 16 200. The exact
molecular weights of the smaller fragments remain undetermined.
All low molecular weight fragments contain the amphipathic
helix region as determined by antibody mapping.
fatty acid also labels membrane-embedded regions of
w xproteins 52 . CT bound to PCroleic acid vesicles
was labeled by this probe, as was the control protein,
apolipoprotein A-I. Ovalbumin was not labeled by
w3 x  .H TUA data not shown . Thus, the results obtained
using two distinct membrane probes confirm that the
membrane-bound form of CT is embedded in the
hydrophobic core of activating membranes.
3.3. Chymotrypsin fragmentation pattern of CT
The products of partial proteolysis of CT by chy-
w xmotrypsin have been previously characterized 19 .
Under those conditions, CT was digested from the
C-terminus to produce discrete fragments of ;39,
35, 30, 28, and 26 kDa which contained the N-termi-
nal domain but were missing different lengths of the
C-terminal region, as mapped using antibodies di-
rected against these regions. The C-terminal residue
 .of each fragment was estimated Fig. 4 based on its
apparent molecular weight and chymotrypsin’s selec-
tivity for large, hydrophobic amino acids. The two
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Fig. 5. Analysis of the high molecular weight fragments derived
w125 x  .from I TID-labeled CT. CT 20 mg per lane was photola-
w125 x  .beled with I TID ;4 mCi in the presence of 0.75 mM
PCroleic acid. Lane 1: undigested sample. Lane 2: digestion by
an endogenous protease. Lane 3: digestion by chymotrypsin at a
 .mass ratio of 100:1 CT:chymotrypsin . Proteins were separated
 .on a 12% gel as described in Section 2.2. A Gel stained with
 .Coomassie blue. B Autoradiograph of dried gel, exposed for 20
h. The position of molecular weight standards is shown.
largest fragments contained the amphipathic helix
region of CT, while the ;30, 28 and 26 kDa
fragment were missing most or all of this region.
Under the current digestion and electrophoresis con-
ditions, fragments of 39, 35 and one in the 30 to 26
 . 3kDa region were produced Fig. 5A , along with a
faint band migrating immediately behind the dye
 .front Fig. 5A, lane 3 .
To further investigate this band, we used a Tricine
gel system, which effectively separates low molecular
weight proteinsrpeptides. Separation revealed four
previously uncharacterized low molecular weight CT
fragments with apparent molecular weights of ;19,
 .17, 15 and 11 kDa. Fig. 6A . The largest of the
fragments reacted with an antibody directed against
 .the C-terminal 13 residues of CT Fig. 6B and all
fragments reacted with an antibody directed against a
33 residue peptide of the amphipathic helix domain
 .Fig. 6C . Sequence analysis revealed that all four
3 The purified CT contains an endogenous proteinase which
partially digests the protein during the incubation at 378C Fig.
.5A, lane 2 . A number of different proteinases have been shown
to produce similar fragmentation patterns for CT, suggesting that
there are a few very sensitive sites in the native protein Craig
.and Cornell, unpublished observation .
fragments have the same N-terminal sequence, begin-
ning at Thr226. As the largest fragment apparent
.masss19 kDa reacted with the C-terminal anti-
body, it is assumed to comprise the entire C-terminal
region, giving it a calculated molecular weight of
16 200. The apparent discrepancy in electrophoretic
mobility may be attributed to its highly phosphory-
w xlated state 24,25 . The three smaller fragments ap-
pear to be produced by progressive digestion of the
C-terminus from the 16.2 kDa fragment. The molecu-
lar weights of these fragments have been estimated at
;14, 12 and 9 kDa based on potential cleavage sites.
The lowest molecular weight fragment would com-
prise the amphipathic helix region with a ;10 amino
acid extension at the N-terminus. The exact C-termi-
nal residue is not known. Thus, in addition to the
susceptible C-terminal cleavage sites which yield the
39 and 35 kDa fragments, a main site for cleavage by
chymotrypsin is at Tyr225, which produces an N-
terminal 26 kDa fragment and a series of low molec-
ular weight fragments derived from the C-terminal
portion containing the amphipathic helix domain.
[125 ]3.4. Localization of the I TID label on the CT
protein
To establish which region of CT becomes mem-
brane embedded, the protein was labeled with
Fig. 6. Antibody mapping of the low molecular weight chy-
 .motryptic fragments of CT. Undigested CT 4 mg, lane 1 , CT
 .  .12 mg digested by chymotrypsin at 1:10 chymotrypsin:CT
 .  .mass ratio lane 2 or 1:8 ratio lane 3 , were electrophoresed on
16.5% Tr3% C Tricine gel system as described in Section 2.2.
 .The gel was Coomassie-stained A , or transferred to PVDF
membrane and immunoreacted with a 1:200 dilution of antibody
 .directed against the amphipathic helix region B , or a 1:1250
 .dilution of antibody directed against the C-terminal region C .
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w125 xI TID in the presence of PCroleic acid vesicles
followed by digestion with chymotrypsin. The chy-
motryptic fragments were separated by electrophore-
sis and the label analysed by autoradiography Fig.
.5 . Low proteinase concentration produced the 39 and
35 kDa fragments, both of which were labeled with
w125 x  .I TID Fig. 5A and B, lane 2 . At high chy-
motrypsinrCT ratios, the 26 kDa fragment was the
 .dominant fragment produced Fig. 5A, lane 3 . This
fragment, which lacks the entire amphipathic helix
region, had only a small amount of label associated
 .Fig. 5B, lane 3 . The protein band near the bottom
of the gel in Fig. 5A, lane 3, corresponds to the low
molecular weight fragments of CT, and was highly
w125 x  .labeled by I TID Fig. 5B, lane 3 .
The low molecular weight fragments of CT, photo-
labeled in the presence of PCroleic acid vesicles,
were separated using the Tricine gel system. Autora-
diography revealed that the fragments at 19, 17, 15
and 11 kDa contained relatively high levels of
w125 x  .I TID label Fig. 7B . These fragments encompass
the amphipathic helix region of CT. In a separate
experiment, the label associated with each CT frag-
 .ment was quantified Table 1 . The 39 and 35 kDa
fragments contained as much or more label as the
Fig. 7. Analysis of the low molecular weight fragments derived
w125 x  .from I TID labeled CT. CT 20 mg was photolabeled with
w125 x  .I TID 0.2 mol%, ;3 mCi in the presence of 0.75 mM
 .PCroleic acid. Lane 1: undigested sample ;1.5 mg . Lane 2:
digestion by chymotrypsin at a mass ratio of 100:1
 .CTrchymotrypsin . Lane 3: chymotrypsinrCT ratio of 1:30.
Proteins were separated on a 16.5%Tr3%C Tricine gel as de-
 .  .scribed in Section 2.2. A Gel stained with Coomassie blue. B
Autoradiograph of dried gel, exposed for 3 days.
Table 1
w125 xExtent of I TID labeling of the fragments of CT
Fragment %Distribution CPMrmg TIDrprotein
of protein protein molar ratio
Undigested CT – 110 1: 4600
39 21 170 1: 3300
35 8 160 1: 4100
26 48 70 1:12000
19 2 1200 1: 1100
17 10 510 1: 3200
15 4 490 1: 3700
11 7 790 1: 3200
peptide – 870 1: 3100
CT or peptide was photolabeled in the presence of PCroleic acid
w125 xwith 0.2 mol% I TID. An aliquot of the CT sample was
 .removed undigested CT , the remainder digested with chy-
motrypsin, and the fragments separated by electrophoresis as
described in Section 2.2. Protein was quantified by densitometry
of the Coomassie stained gel, normalized to a CT standard. The
percent distribution of protein mass among the fragments is
given. 125I was quantified by gamma-counting of the excised
bands. Mol CT was estimated from the quantified mass of protein
using the estimated true molecular weights for each fragment of
16, 14, 12 and 9 kDa. Moles of TID were calculated from CPM
w125 xand specific activity of the I TID.
 .whole CT 110–170 cpmrmg , while the dominant
Coomassie-stained 26 kDa fragment contained less
 .label 70 cpmrmg . The low molecular weight frag-
ments were more enriched in label than the whole CT
 .molecule 500–1200 cpmrmg . This pattern is con-
sistent with the amphipathic helix region, contained
in the low molecular weight fragments but lacking in
the 26 kDa fragment, playing the key role in mem-
brane intercalation.
[125 ]3.5. I TID Photolabeling of CT in the presence of
PCrdiacylglycerol ˝esicles or Triton X-100 micelles
In addition to anionic lipids, typified by PCroleic
acid vesicles, CT is also activated by membranes
containing diacylglycerol. As synthetic peptide corre-
w xsponding to the three 11-mer repeats 32 did not bind
to PC vesicles containing diacylglycerol. This raised
the possibility that the diacylglycerol-sensor is out-
side of the amphipathic helix. To probe the interac-
tion of whole CT with diacylglycerol-containing
w125 xmembranes, I TID labeling of CT was attempted
in the presence of egg PCrdiacylglycerol vesicles
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 .4:1 , using conditions for complete membrane asso-
ciation established for PCroleic acid vesicles Fig.
.2 . We also photolabeled CT in its Triton X-100
 .micelle-bound state Triton:CT ratio(100 . Photola-
beling efficiencies were similar to that obtained using
 .PCroleic acid vesicles data not shown . CT was
subsequently digested with chymotrypsin and the
fragments separated on the Tricine gel system. The
w125 xfragmentation pattern of CT and I TID labeling
patterns obtained in the presence of PCrdi-
 .acylglycerol or Triton data not shown were identi-
cal to those obtained in the presence of PCroleic
 .acid Fig. 7 . The whole enzyme and the large 39 and
35 kDa fragments contained associated label. The
low molecular weight fragments containing the am-
phipathic helix region of the enzyme contained the
large majority of the label, while the 26 kDa frag-
ment lacking this region was not highly labeled.
Thus, the intercalation of CT into PCrdiacylglycerol
membranes or pure Triton micelles involves the same
amphipathic helix region involved in interaction with
anionic membranes.
3.6. Photolabeling of a peptide corresponding to the
entire amphipathic helical domain
Analysis of digested, photolabeled CT supports
our hypothesis for the amphipathic helix region as the
membrane-binding domain. To further substantiate
this model, we obtained a 62 residue peptide corre-
sponding in sequence to the entire proposed amphi-
 .pathic helical domain of CT residues 238–299 . This
peptide has a molar partition coefficient for PCroleic
 . 5acid 1:1 vesicles of 2=10 , and adopts an a-heli-
cal conformation in response to lipid vesicles or
detergent micelles, as analysed by CD and 2D-NMR
w x w125 x66 . This peptide was photoreacted with I TID in
presence of PCroleic acid and was separated from
lipid on a 16.5%T, 6% C Tricine gel system. The
w125 x  .peptide was highly labeled by I TID Table 1 .
w125 xThe efficiency of I TID incorporation into the
peptide was 0.05 to 0.08%, slightly higher than that
obtained for the whole enzyme. The radioactivity per
mg of peptide was similar to that obtained for the low
 .molecular weight fragments of CT Table 1 . At 0.2
w125 xmol% I TID, 1 in 3100 peptide molecules became
w125 xassociated with I TID. These results confirm that
this region of the protein can intercalate into mem-
branes independently of the rest of the protein. We
w125 xattempted N-terminal sequencing of I TID labeled
peptide, as well as the low molecular weight chy-
motrypsin fragments, to identify the labeled amino
acids, but the degree of labeling was insufficient, and
all cycles in the Edman degradation contained back-
ground levels of radioactivity.
4. Discussion
4.1. The CT-membrane interaction in˝ol˝es intercala-
tion into the hydrophobic membrane core
In this report, we have used the photoreactive
w125 xprobe I TID to investigate the mechanism of the
w125 xCT-membrane interaction. The fact that I TID
significantly labels CT suggests a mechanism of
membrane interaction whereby the protein interca-
lates into the hydrophobic membrane core. It is well
accepted that CT interacts with membranes, but the
mechanism of membrane interaction is not known.
There are several lines of evidence to suggest that the
binding is not solely a peripheral charge interaction
between protein and lipid head groups, but that an
actual penetration to the hydrophobic core is in-
volved. While ionic strength effects the enzyme activ-
w xity 6 , high salt is insufficient to extract enzyme from
w xthe membrane; detergents are needed 8 . Intercala-
tion was postulated due to dependence of activity on
a fluid membrane phase, enhancement of activity at
the phase transition and dependence on bilayer curva-
w xture 10 . Intercalation has been demonstrated for
synthetic peptides corresponding in sequence to a
proposed membrane-binding region of the protein
w x32 . Thus, although pre˝ious studies had suggested
that the protein is embedded in the hydrophobic core
of the membrane, this had ne˝er been demonstrated
directly using the purified nati˝e enzyme.
w125 xThe degree of labeling with I TID is consistent
with an interaction of CT involving membrane inter-
w125 xcalation. While the I TID labeling efficiency de-
pends on the mol percent and type of protein in the
membrane as well as the reaction efficiency of TID
under the irradiation conditions used, a range of
w125 x0.5–0.01% of the I TID generally becomes incor-
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w xporated into membrane-embedded proteins 35 . The
w125 xI TID labeling efficiency of CT, 0.03 to 0.05%,
falls within this range. A bromelain-released soluble
fragment of hemagglutinin lacking the trans-mem-
 . w125 xbrane anchor BHA2 was I TID labeled with an
efficiency of 0.025% using conditions similar to ours
w x w125 x43 . The key region of BHA2 labeled by I TID
was a small membrane-interacting region proposed to
be involved in fusion. Both CT and Apo A-I were
w125 xlabeled to a similar extent with I TID, and both
are postulated to bind as amphipathic helices oriented
with helix axes parallel to the membrane surface.
4.2. The amphipathic helix of CT is the key region
in˝ol˝ed in intercalation
The results obtained using proteolysis of CT in
combination with photolabeling demonstrate the key
role of the amphipathic helix region in the membrane
intercalation of the protein. The 39 and 35 kDa
N-terminal fragments containing this region were
associated with the hydrophobic photolabel, while the
26 kDa fragment lacking this region contained a low
level of labeling. We have identified low molecular
weight fragments that had not been previously char-
w xacterized 19 due to the gel conditions and antibodies
used for detection in that study. These fragments,
with molecular weights in the range of ;9 kDa to
16 kDa, comprise the entire amphipathic helix region
as well as various lengths of the C-terminal domain.
The persistence of these fragments demonstrates the
resistance of the amphipathic helix region to diges-
tion, consistent with a membrane-bound location
where it would be inaccessible to the proteinase. The
w125 xhigh I TID labeling of the low molecular weight
fragments comprising the amphipathic helix region
demonstrates the key role for this region in CT
membrane binding. A synthetic peptide correspond-
ing in sequence to the amphipathic helix region be-
came labeled to the same extent as these fragments,
substantiating our conclusion that this region func-
tions as the key membrane binding site for CT. This
finding also validates the use of synthetic peptides as
models for CT binding to anionic lipids.
w125 xThe same region of CT is labeled by I TID
whether the lipid vesicles contain oleic acid or dia-
cylglycerol. Since the amphipathic peptide does not
w xbind to diacylglycerol-containing vesicles 53 some
region other than the amphipathic helix residues
.238–299 may be needed to impart sensitivity to
diacylglycerol. Despite this difference, the same do-
main mediates intercalation into membranes contain-
ing either oleic acid or diacylglycerol. The amphi-
pathic helix was also the key photolabeled domain of
Triton X-100-bound CT. Since the enzyme is not
activated by Triton X-100, this finding suggests that
mere intercalation of the amphipathic helix into a
hydrophobic environment is not sufficient for conver-
sion to the active conformation.
All previous observations in addition to the present
data are consistent with a mode of interaction involv-
ing an amphipathic helix domain lying with its axis
parallel to the surface of membrane, with the non-
polar face embedded to the acyl chain region of the
membrane, and polar face interacting with lipid head
groups, the aqueous solution or a distinct part of the
protein. The amphipathic helix domain does not form
a specific ‘binding pocket’ designed to interact with a
specific head group or with lipid monomers as in the
w xcase of the C1 domain of protein kinase C 54 or the
w xlipid binding sites of lipases 55,56 , but rather forms
a relati˝ely non-specific, low affinity hydrophobic
surface. With a structural reorganization, an amphi-
pathic helix has the potential to convert between a
structure compatible with a soluble or a membrane-
bound form. For example, the solution form of insect
apolipophorin is a five amphipathic-helix bundle with
the hydrophobic faces in the interior which, in a
reversible manner, spreads open on the membrane
surface to expose the hydrophobic faces of the he-
lices to the membrane without disrupting the sec-
w xondary structure 57 . Similarly, the pore-forming
amphipathic helix bundles of diphtheria toxin, colicin
A, endotoxin, and exotoxin turn ‘inside-out’ to ex-
pose non-polar residues to the surface of membranes
w x58 . A tertiary structural reorganization that retains
the secondary structure of the amphipathic helix could
account for the conversion of CT between mem-
brane-bound and soluble forms. The amphipathic he-
lix region has been proposed to form an autoin-
hibitory domain, which would be displaced from the
catalytic domain upon membrane binding, thereby
w xactivating the enzyme 33 . Unfortunately, the lipid
free form of purified CT forms insoluble aggregates
w x51 , which make it unamenable to TID photolabel-
ing.
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[125 ]4.3. I TID weakly labels the catalytic domain of
CT
There was some label found in the 26 kDa frag-
ment, which appeared to be more than just back-
w125 xground. I TID has a partition coefficient for egg
4 w xPC or red cell membranes of 4=10 37 , which in
our system 500 ml solution volume, ;0.17 mg
.lipid would result in 93% of the TID partitioning
into the vesicles, and 7% into the aqueous phase.
Lack of significant labeling of ovalbumin suggests
that this small amount of free TID does not con-
tribute to the labeling of soluble proteins. CT is not a
soluble protein, and the proximity of the N-terminal
region to the vesicle may contribute to the small
amount of labeling. When labeling the integral Fo
subunits of Escherichia coli ATP synthase, a periph-
 .eral F subunit b became associated with a low1
w125 xlevel of label, suggesting that I TID can react with
w xperipheral membrane proteins 59 . While the N-
terminal region of CT does not associate with mem-
w xbranes on its own 19,25,33 , a small portion could
penetrate the membrane as this region is held in close
proximity to the membrane surface by the amphi-
pathic helix.
Non-membrane proteins have been photolabeled
w125 xwith I TID in the absence of lipid. It is thought
w125 xthat I TID probes for hydrophobic patches or
pockets in the soluble proteins. Hydrophobic sites in
w x w x w xcalmodulin 60 , troponin C 61 and lactalbumin 62
involved in the interaction with target proteins have
w125 x 2qbeen labeled by I TID in a Ca dependent man-
ner in the absence of lipids. A cytochrome P-450
w x w x63 , prostaglandin endoperoxide H synthase-1 64 ,
q w xand an H -ATPase from yeast 65 were labeled in
their membrane-embedded regions, and also in solu-
ble domains containing hydrophobic substrate-bind-
ing pockets. While the active sites of cytochrome
P-450 and PGHS-1 would be designed to accommo-
date hydrophobic substrates, the active site for the
Hq-ATPase may more closely resemble the active
site of CT, since both catalyze nucleotide reactions.
Little is known about the environment of the active
w xsite of CT 23 . There may exist a hydrophobic
pocket involved in substrate binding, or interaction
with the hydrophobic portion of the amphipathic
helix when the protein is in its soluble form.
In summary, the binding of CT to membranes
involves an intercalation of the amphipathic a-helical
region into the hydrophobic core of the membrane.
The structural changes involved in this reversible
interaction, and the mechanism whereby these
changes activate the enzyme are now key questions
in the elucidation of the regulation this enzyme.
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